

CORRECTION - Financial agenda for 2025

Villepinte, 13 January 2025: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is announcing its financial agenda for 2025.

Publications calendar
 2024 ANNUAL REVENUE February 06, 2025, after trading
 2024 ANNUAL RESULTS March 26, 2025, after trading
2025 1 ST QUARTER REVENUE April 24, 2025, after trading
ANNUAL SHAREHOLDERS' MEETING May 23, 2025
• 2025 2 ND QUARTER REVENUE July 24, 2025 , after trading
2025 FIRST HALF RESULTS September 24, 2025, after trading
2025 3 RD QUARTER REVENUE October 23, 2025, after trading

Contacts:

Guerbet

Jérôme Estampes, Chief Financial Officer + 33 1 45 91 50 00 / jerome.estampes@guerbet.com Christine Allard, Head of Public Affairs and Communications: +33 6 30 11 57 82 / christine.allard@guerbet.com











PRESS RELEASE



About Guerbet

At Guerbet, we build lasting relationships so that we enable people to live better. That is our purpose. We are a leader in medical imaging worldwide, offering a comprehensive range of pharmaceutical products, medical devices, and digital and AI solutions for diagnostic and interventional imaging. A pioneer in contrast media for 95 years, with more than 2,600 employees worldwide, we continuously innovate and devote 10% of our sales to research and development in four centres in France, in United States and Israël. Guerbet (GBT) is listed on Euronext Paris (segment B − mid caps) and generated €786 million in revenue in 2023.

Contacts:

Guerbet

Jérôme Estampes, Chief Financial Officer + 33 1 45 91 50 00 / jerome.estampes@guerbet.com Christine Allard, Head of Public Affairs and Communications: +33 6 30 11 57 82 / christine.allard@guerbet.com











